LearnGlossaryMarketStocksSuperinvestorsSign in

MGX

Metagenomi, Inc. Common Stock

Healthcare · $43M market cap

Verdict

We can't put a fair value on MGX right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth—?
Sales growth15.2% a year✓
Free cash flow growth-26.3% a year✗
Return on invested capital-33.9%✗

Follow MGX

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 8, 2026: 2 open-market purchases worth $23K and 3 sales worth $5K. Why purchases matter

Purchases

Reid Laurence

director · 2026-09-09

Bought

$138

Reid Laurence

director · 2026-09-09

Bought

$23K

Sales

Wapnick Pamela

Chief Financial Officer · 2026-09-08

Sold

$2K

Irish Jian

See Remarks · 2026-09-08

Sold

$2K

Wein Matthew

See Remarks · 2026-09-08

Sold

$415

About Metagenomi, Inc. Common Stock

Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works